A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Imagine Institute
University of Nebraska
National Institutes of Health Clinical Center (CC)
University of Nottingham
Mayo Clinic
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Singapore General Hospital